Dicerna Pharmaceuticals, Inc.
Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA

Abstract:

This invention relates to compounds, compositions, and methods useful for reducing KRAS target RNA and protein levels via use of Dicer substrate siRNA (DsiRNA) agents possessing asymmetric end structures.